<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845139</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0139</org_study_id>
    <nct_id>NCT04845139</nct_id>
  </id_info>
  <brief_title>A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma</brief_title>
  <official_title>A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Nivolumab given intrathecally is effective&#xD;
      in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a case study aiming to recruit 1 patient. This study is indicated for&#xD;
      relapsed/refractory primary central nervous system lymphoma. Primary objective is to explore&#xD;
      the safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>On a continuous basis up to 1 month after the first dose of study drug</time_frame>
    <description>Adverse events Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response(BOR)</measure>
    <time_frame>up to 3 months after the first dose of study drug</time_frame>
    <description>Record individual best overall response(BOR), including CR, PR, SD, PD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Refractory Central Nervous System Lymphoma</condition>
  <condition>Relapsed Primary Central Nervous System Lymphoma</condition>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab administration Q2W intrathecally by lumbar punctuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab given intrathecally</description>
    <arm_group_label>Nivolumab administration</arm_group_label>
    <other_name>NIVO；Opdivo; BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with ECOG 0,1,2,3&#xD;
&#xD;
          -  Subjects with pathologically confirmed PCNSL with lesion in brain who progressed after&#xD;
             or did not respond to at least 1 line of systemic therapy. PCNSL prior therapy may&#xD;
             include HD-MTX, HD-MTX-based regimen, high-dose cytarabine, radiation therapy alone as&#xD;
             treatment or as part of consolidation therapy, high-dose therapy with autologous stem&#xD;
             cell transplant as part of consolidation therapy, and/or intraocular MTX alone or as&#xD;
             part of consolidation therapy&#xD;
&#xD;
          -  Subject with sufficient function of liver, kidney, heart, lung and hematopoiesis&#xD;
&#xD;
          -  Subjects with relapsed PCNSL and are able to receive biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects that are not DLBCL type pathologically&#xD;
&#xD;
          -  Intraocular PCNSL without evidence of brain disease&#xD;
&#xD;
          -  Subjects who cannot undergo MRI assessments&#xD;
&#xD;
          -  Relapsed PCNSL patients who cannot undergo biopsy&#xD;
&#xD;
          -  Biopsy suggests no significant tumor-infiltration T cell or poor PD-1 expression&#xD;
&#xD;
          -  Subjects with other malignancy&#xD;
&#xD;
          -  Subjects with history of any inflammatory CNS diseases&#xD;
&#xD;
          -  Subjects with an active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications within 14 days of start of study treatment&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Zhang, M.D.</last_name>
    <phone>0086-0571-87784755</phone>
    <email>zjm135@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jianmin Zhang</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Zhang, M.D., Ph.D.</last_name>
      <phone>+86 0571 87784755.</phone>
      <email>zjm135@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jianmin Zhang, M.D.，Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

